Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Wins SBIR Grant for ALS Biomarker Identification

NEW YORK, April 12 (GenomeWeb News) - Metabolon has received a Small Business Innovation Research grant for an undisclosed amount from the NIH to study biomarkers for amyotrophic later sclerosis, the company said today.

 

Metabolon will use its metabolomics platform to test plasma samples obtained from patients to identify ALS biomarkers, the company said in a statement. Metabolon will then compare these biomarkers with those from other motor neuron diseases, and will study how biomarkers for the disease change with its progression.

 

The grant was awarded by the NIH's National Institute of Environmental Health Sciences, and is the third award for ALS studies Metabolon has received since the beginning of 2004.

 

In August, Metabolon received a grant from the National Institute of Neurological Disorders and Stroke to study ALS biomarkers in collaboration with Massachusetts General Hospital. In February 2004, the company received an award from the ALS Association.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.